Generalized joint laxity at baseline does not affect fusion rate or clinical outcomes
BY
ADMIN / TUESDAY, 01 MARCH 2016 /
Generalized joint laxity at baseline does not affect fusion rate or clinical outcomes. According
to findings in a recently published study, generalized joint laxity has little effect on fusion rates or the clinical outcomes of pain intensity and functional status, but it may have a negative effect on adjacent segment pathology after posterior lumbar interbody fusion.
to findings in a recently published study, generalized joint laxity has little effect on fusion rates or the clinical outcomes of pain intensity and functional status, but it may have a negative effect on adjacent segment pathology after posterior lumbar interbody fusion.
Researchers
conducted a retrospective comparative study that included 37 patients with
generalized joint laxity (GJL) and 219 patients without GJL. The two groups
were followed for 2 years after undergoing posterior lumbar interbody fusion
(PLIF), with the researchers comparing fusion rates, low back pain intensity on
a VAS and functional outcome based on the Oswestry Disability Index (ODI)
between the two groups.
Two
years after surgery, 91.9% of patients with GJL and 91.8% of patients without
GJL experienced successful fusion, according to radiographic images in the
study.
Both
groups experienced significant decreases in VAS scores for low back pain, with
improvements in pain intensity of 75.1% for the GJL group and 77.9% in the
non-GJL group; however, the difference between the groups for low back pain, as
well as the difference between the groups for ODI score, was not considered
statistically significant, according to the researchers.
The
researchers observed adjacent segment pathology to be present in both the
superior and inferior segments within both groups, but this was also not
considered to be significantly different between the two groups.
Patients
in the GJL group were observed to have a greater degree of severe degeneration
based on modified Pfirrmann classification compared with patients without GJL,
which was considered a statistically significant difference, according to the
researchers.
The
researchers concluded that although GJL may contribute to the worsening or
loosening of adjacent segment pathology, GJL at baseline does not affect fusion
rates or clinical outcomes.
Read
more: www.IntegrityLifeSciences.com or www.AxiomWorldwide.com
As
Published in the Medical News
Integrity
Life Sciences has been exclusively granted the use of all of the technology,
products, US Patent and Trademark Office’s assignments, logos and other forms
of intellectual property that were created by Axiom Worldwide, Inc. The
agreement specifically includes the flagship product DRX9000
No comments:
Post a Comment